Decreased responsiveness of vascular postjunctional alpha1-, alpha2-adrenoceptors and neuropeptide Y1 receptors in rats with heart failure.
Heart failure is associated with increased sympathetic nerve activity. We hypothesized that chronic sympathetic stimulation in heart failure resulted in decreased vascular sympathetic responsiveness. A pithed rat model was employed to evaluate peripheral vascular alpha-adrenoceptor and neuropeptide Y (NPY) receptor responsiveness. Heart failure was induced in Sprague-Dawley rats by coronary artery ligation. Sham operated rats (Sham) served as controls. Two months after this surgical procedure, both heart failure (n = 30) and Sham (n = 30) rats underwent standard pithing procedure. Pressor responses to preganglionic sympathetic nerve stimulation (PNS) and activation of postjunctional alpha1- and alpha2-adrenoceptors as well as Y1 receptors were studied. In response to PNS, cardiac index was similar between heart failure and sham rats (P = n.s.). Mean arterial pressure (MAP) increased in a frequency-dependent fashion after PNS in heart failure rats as well as in control rats. All the agonists used, i.e. the alpha1-adrenoceptor agonist phenylephrine, the alpha2-adrenoceptor agonists clonidine and BHT933 as well as NPY, induced dose-dependent increases in MAP in heart failure and in sham rats. However, in rats with heart failure, the response to all the agonists studied was significantly decreased and the dose response curves were shifted to the right (P < 0.01). We conclude that in vivo vascular response to postjunctional alpha1- and alpha2-adrenoceptors as well as Y1 receptors are decreased in rats with heart failure.
Feng
Q
Q
Departments of Medicine, Pharmacology and Toxicology, University of Western Ontario, London, Ontario, Canada.
Sun
X
X
Lu
X
X
Edvinsson
L
L
Hedner
T
T
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood; D001339:Autonomic Fibers, Preganglionic / Q000187:drug effects / Q000502:physiology; D001381:Azepines / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002302:Cardiac Output / Q000502:physiology; D002395:Catecholamines / Q000097:blood; D003000:Clonidine / Q000494:pharmacology; D003655:Decerebrate State / Q000503:physiopathology; D004558:Electric Stimulation; D006333:Heart Failure / Q000503:physiopathology*; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology; D010656:Phenylephrine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology*; D018341:Receptors, Adrenergic, alpha-2 / Q000502:physiology*; D017476:Receptors, Neuropeptide Y / Q000819:agonists / Q000502:physiology*
D000316:Adrenergic alpha-Agonists; D001381:Azepines; D002395:Catecholamines; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; D017476:Receptors, Neuropeptide Y; C097212:neuropeptide Y-Y1 receptor; D010656:Phenylephrine; D009320:Atrial Natriuretic Factor; C015603:azepexole; D003000:Clonidine